Avalo Therapeutics Inc AVTX

5d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Avalo Therapeutics' Newly Acquired Ex-Eli Lilly Drug Could Stand Out In Competitive Hidradenitis Suppurativa Market, Analyst Upgrades

7d ago, source:

Unlock the potential of Avalo Therapeutics with AVTX-009, a promising drug for hidradenitis suppurativa. Oppenheimer upgrades ...

Will Avalo Therapeutics, Inc. (AVTX) Report Negative Q4 Earnings? What You Should Know

27d ago, source: Zacks.com on MSN

T he market expects Avalo Therapeutics, Inc. (AVTX) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended December 2023. This widely ...

Avalo Therapeutics Appoints Biotech Leaders to Board of Directors

21d ago, source: Business Insider

and ROCKVILLE, Md., April 02, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced the addition of multiple biotech leaders to its Board of Directors. The Avalo Board ...

Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million

26d ago, source: Stockhouse

and ROCKVILLE, Md., March 27, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced it has acquired a Phase 2-ready anti-IL-1ß mAb, which it refers to as AVTX-009, through ...

Avalo Therapeutics Inc

26d ago, source: CNN

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network.

Avalo Therapeutics: Avalo Acquires Anti-IL-1ß mAb and Announces Private Placement Financing of up to $185 Million

27d ago, source: Finanznachrichten

and ROCKVILLE, Md., March 27, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced it has acquired a Phase 2-ready anti-IL-1ß mAb, which it refers to as AVTX-009 ...

Avalo Therapeutics Inc AVTX

5d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Avalo Therapeutics Inc.

27d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...